A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyÖ. Türeci, Martin Schüler, Uğur Şahin et al.|Annals of Oncology|2019Cited by 244
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Matthias Biebl, Nils Homann et al.|Journal of Clinical Oncology|2023Cited by 192